A promising inactivated whole-virion SARS-CoV-2 vaccine
| Media Type: |
Electronic Article |
|---|
| Year of Publication: |
2021 |
|---|
| Contained In: |
The Lancet. Infectious diseases - Vol. 21, No. 1 (2021), p. 2-3 |
|---|
| Language: |
English |
|---|
| Contributors: |
|---|
| Urls: |
|---|
| Keywords: |
Adolescent |
|---|
| Notes: |
Date Completed 13.01.2021 Date Revised 13.01.2021 published: Print-Electronic Citation Status MEDLINE Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine |
|---|
| Physical Description: |
Online-Ressource |
|---|
| doi: |
10.1016/S1473-3099(20)30832-X |
|---|---|
| PMID: |
33069282 |
| PPN (Catalogue-ID): |
NLM31736149X |
|---|
| LEADER | 02009nma a2200565 c 4500 | ||
|---|---|---|---|
| 001 | NLM31736149X | ||
| 003 | DE-601 | ||
| 005 | 20210114213648.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201019s2021 000 0 eng d | ||
| 024 | 7 | |a 10.1016/S1473-3099(20)30832-X |2 doi | |
| 028 | 5 | 2 | |a pubmed21n1110.xml |
| 035 | |a S1473-3099(20)30832-X | ||
| 035 | |a (DE-599)NLM33069282 | ||
| 040 | |b ger |c GBVCP | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Isakova-Sivak, Irina | |
| 245 | 1 | 2 | |a A promising inactivated whole-virion SARS-CoV-2 vaccine |h Elektronische Ressource |
| 300 | |a Online-Ressource | ||
| 500 | |a Date Completed 13.01.2021 | ||
| 500 | |a Date Revised 13.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 500 | |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine | ||
| 611 | 2 | 7 | |a Journal Article |2 gnd |
| 653 | 2 | |a Adolescent |6 D000293 | |
| 653 | 2 | |a Adult |6 D000328 | |
| 653 | 2 | |a Aged |6 D000368 | |
| 653 | 2 | |a COVID-19 |6 D000086382 |a *prevention & control |6 Q000517 | |
| 653 | 2 | |a COVID-19 Vaccines |6 D000086663 |a adverse effects |6 Q000009 |a *immunology |6 Q000276 | |
| 653 | 2 | |a Clinical Trials as Topic |6 D002986 | |
| 653 | 2 | |a Humans |6 D006801 | |
| 653 | 2 | |a Middle Aged |6 D008875 | |
| 653 | 2 | |a SARS-CoV-2 |6 D000086402 |a *immunology |6 Q000276 | |
| 653 | 2 | |a Vaccines, Inactivated |6 D015164 |a immunology |6 Q000276 | |
| 653 | 2 | |a Virion |6 D014771 |a *immunology |6 Q000276 | |
| 653 | 2 | |a Young Adult |6 D055815 | |
| 655 | 7 | |a COVID-19 Vaccines |2 gnd | |
| 655 | 7 | |a Vaccines, Inactivated |2 gnd | |
| 689 | 0 | 0 | |A f |a Journal Article |
| 689 | 0 | |5 DE-601 | |
| 689 | 2 | 0 | |a COVID-19 Vaccines |
| 689 | 2 | 1 | |a Vaccines, Inactivated |
| 689 | 2 | |5 DE-601 | |
| 700 | 1 | |a Rudenko, Larisa | |
| 773 | 0 | 8 | |i in |t The Lancet. Infectious diseases |g Vol. 21, No. 1 (2021), p. 2-3 |q 21:1<2-3 |w (DE-601)NLM117567582 |x 1474-4457 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/S1473-3099(20)30832-X |3 Volltext |
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 1 |b 15 |c 01 |h 2-3 | ||